Suppr超能文献

冬季一种作为附加疗法的新光疗方案,联合口服维生素D补充剂,用于特应性皮炎的长期控制:一项多中心、随机、交叉、实用试验的研究方案——PRADA试验

A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial.

作者信息

Droitcourt Catherine, Barbarot Sébastien, Maruani Annabel, Darrieux Laure, Misery Laurent, Brenaut Emilie, Adamski Henri, Chabbert Cécile, Vermersch Annie, Weiborn Marie, Seneschal Julien, Taïeb Alain, Plantin Patrice, Maillard Hervé, Phan Alice, Skowron François, Viguier Manuelle, Staumont-Salle Delphine, Nosbaum Audrey, Soria Angèle, Barbaud Annick, Oger Emmanuel, Dupuy Alain

机构信息

Univ Rennes, Rennes, France.

Department of Dermatology, University Hospital Center of Rennes, Pontchaillou Hospital, 2 rue Henri le Guilloux, 35000, Rennes, France.

出版信息

Trials. 2019 Mar 25;20(1):184. doi: 10.1186/s13063-019-3276-9.

Abstract

BACKGROUND

Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despite long-term control having been acknowledged as one of the most important core outcome domains to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates.

METHODS

This is a multicenter, national, randomized, superiority, crossover trial testing add-on phototherapy (one winter under spaced sessions of phototherapy and one winter under observation) among subjects receiving standard care (i.e., TAT). On the same population, we will test the long-term control provided by oral supplementation of vitamin D versus placebo in a randomized, superiority, double-blind, parallel-group trial. The primary outcomes are (1) repeat measures of the PO-SCORAD severity score over 1 year and (2) cumulate consumption of TAT (number of tubes) during the winter. They will be tested following a hierarchical testing procedure. The secondary outcomes will be measures repeated over 2 years of investigator-based severity scores, patient-reported severity and quality of life scores, serum vitamin D levels, weeks during which the disease is well-controlled, inter-visit cumulate consumption of TAT, and synthetic patient-reported satisfaction at the end of each winter.

DISCUSSION

This study includes two separate 2-year pragmatic trials designed to evaluate the efficacy of vitamin D supplementation and pro-active phototherapy for primary care atopic dermatitis patients receiving TAT on long-term control of disease activity. The experimental design enables the study of both interventions and exploration of the interaction between vitamin D and phototherapy. A pragmatic trial is particularly suited to the assessment of long-term control. This study explores the possibility of new and safe therapeutic strategies for the control of long-term atopic dermatitis, and is an example of efficacy research that is unlikely to be sponsored by industrialists. A potentially effective low-cost therapeutic strategy for long-term control is essential for patients and public health.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier: NCT02537509 , first received: 1 September 2015.

摘要

背景

特应性皮炎是一种在成人和儿童中都高度流行的慢性复发性疾病。在疾病严重程度谱上,病情较轻的患者受益于少量局部抗炎治疗(TAT),而病情较重的患者则需要全身免疫抑制剂;介于两者之间的患者则接受TAT和光疗。该人群的主要治疗挑战是疾病活动的长期控制,而目前基于TAT的积极治疗策略并不能满足他们的所有需求。免疫抑制剂被用作长期控制的附加治疗,但由于安全问题,它们仅限于最严重受影响的患者。此外,尽管长期控制被认为是特应性皮炎试验中最重要的核心结局领域之一,但免疫抑制剂和其他策略都没有得到长期的适当评估。因此,需要经过严格评估以实现疾病长期控制的安全附加疗法。光疗和补充维生素D都是很好的选择。

方法

这是一项多中心、全国性、随机、优效性、交叉试验,在接受标准治疗(即TAT)的受试者中测试附加光疗(一个冬季进行间隔光疗,另一个冬季进行观察)。在同一人群中,我们将在一项随机、优效性、双盲、平行组试验中测试口服补充维生素D与安慰剂相比提供的长期控制效果。主要结局是:(1)1年内PO-SCORAD严重程度评分的重复测量值,以及(2)冬季期间TAT的累积消耗量(管数)。将按照分层检验程序对它们进行检验。次要结局将是基于研究者的严重程度评分、患者报告的严重程度和生活质量评分重复测量2年的结果、血清维生素D水平、疾病得到良好控制的周数、访视期间TAT的累积消耗量,以及每个冬季结束时患者报告的综合满意度。

讨论

本研究包括两项独立的为期2年的实用试验,旨在评估补充维生素D和积极光疗对接受TAT的基层医疗特应性皮炎患者疾病活动长期控制的疗效。实验设计能够对两种干预措施进行研究,并探索维生素D与光疗之间的相互作用。实用试验特别适合评估长期控制效果。本研究探索了控制特应性皮炎长期病情的新的安全治疗策略的可能性,是一项不太可能由产业界资助的疗效研究实例。一种潜在有效的低成本长期控制治疗策略对患者和公共卫生至关重要。

试验注册

ClinicalTrials.gov标识符:NCT02537509,首次收到时间:2015年9月1日。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验